HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Patricia Gilleaudeau Selected Research

Haptens

10/2014Molecular characterization of human skin response to diphencyprone at peak and resolution phases: therapeutic insights.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Patricia Gilleaudeau Research Topics

Disease

13Psoriasis (Pustulosis Palmaris et Plantaris)
01/2017 - 02/2003
9Atopic Dermatitis (Atopic Eczema)
01/2022 - 09/2011
6Inflammation (Inflammations)
01/2021 - 11/2010
3Hyperplasia
01/2021 - 06/2014
2Alopecia Areata
10/2022 - 01/2022
2Alopecia (Baldness)
10/2022 - 01/2022
2Melanoma (Melanoma, Malignant)
01/2019 - 10/2016
2Infections
04/2016 - 12/2005
1Hidradenitis Suppurativa
11/2020
1Vitamin D Deficiency
01/2017
1Neoplasm Metastasis (Metastasis)
10/2016
1Pigmented Nevus (Melanocytic Nevus)
10/2016
1Wounds and Injuries (Trauma)
04/2016
1Hypersensitivity (Allergy)
10/2014
1Necrosis
03/2013
1Vitiligo
04/2011
1Skin Neoplasms (Skin Cancer)
09/2010
1Thrombosis (Thrombus)
03/2010
1Thrombocytosis (Thrombocythemia)
03/2010
1Rheumatoid Arthritis
03/2010
1Autoimmune Diseases (Autoimmune Disease)
06/2007
1Graft vs Host Disease (Graft-Versus-Host Disease)
06/2007
1Skin Diseases (Skin Disease)
02/2005

Drug/Important Bio-Agent (IBA)

4CytokinesIBA
01/2019 - 04/2012
4efalizumab (Raptiva)FDA Link
01/2012 - 10/2004
3Proteins (Proteins, Gene)FDA Link
01/2017 - 12/2007
3Biomarkers (Surrogate Marker)IBA
06/2014 - 06/2007
3Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA
03/2010 - 12/2005
3Alefacept (Amevive)FDA Link
06/2007 - 02/2005
2dupilumabIBA
10/2022 - 01/2022
2SaltsIBA
10/2022 - 01/2022
2Monoclonal AntibodiesIBA
01/2022 - 01/2018
2Interleukin-22 (IL-22)IBA
01/2019 - 01/2018
2fezakinumabIBA
01/2019 - 01/2018
2Interleukin-12 (IL 12)IBA
01/2017 - 02/2003
2diphenylcyclopropenoneIBA
10/2016 - 10/2014
2Cyclosporine (Ciclosporin)FDA LinkGeneric
10/2014 - 06/2014
2Messenger RNA (mRNA)IBA
04/2011 - 02/2003
2Interleukin-17 (Interleukin 17)IBA
04/2011 - 11/2010
1Lipocalin-2IBA
01/2021
1loricrinIBA
01/2021
1MART-1 AntigenIBA
01/2021
1S100 Calcium Binding Protein A7IBA
01/2021
1Filaggrin ProteinsIBA
01/2021
1brodalumabIBA
11/2020
1LipidsIBA
01/2017
1Ustekinumab (CNTO 1275)FDA Link
01/2017
1Cholecalciferol (Vitamin D3)FDA Link
01/2017
125-hydroxyvitamin DIBA
01/2017
1hydroxide ionIBA
01/2017
1Complementary DNA (cDNA)IBA
10/2016
1trichohyalinIBA
10/2016
1Keratins (Keratin)IBA
10/2016
1Pancreatic Ribonuclease (Ribonuclease A)IBA
10/2016
1Ribonucleases (Ribonuclease)IBA
10/2016
1Petrolatum (Vaseline)FDA Link
04/2016
1SteroidsIBA
01/2016
1HaptensIBA
10/2014
1Interleukin-13IBA
06/2014
1ElafinIBA
06/2014
1Protease Inhibitors (Protease Inhibitor)IBA
06/2014
1Tumor Biomarkers (Tumor Markers)IBA
03/2013
1TNF-Related Apoptosis-Inducing LigandIBA
03/2013
1ChemokinesIBA
04/2012
1InflammasomesIBA
04/2011
115-hydroxyprostaglandin dehydrogenaseIBA
09/2010
1Hemostatics (Antihemorrhagics)IBA
03/2010
1InterleukinsIBA
03/2010
1Tumor Necrosis Factor Receptors (Tumor Necrosis Factor Receptor)IBA
12/2007
1Etanercept (Enbrel)FDA Link
12/2007
1Biological ProductsIBA
12/2007
1Immunoglobulins (Immunoglobulin)IBA
12/2007
1Nitric Oxide Synthase Type II (Inducible Nitric Oxide Synthase)IBA
12/2005
1Nitric Oxide (Nitrogen Monoxide)FDA Link
12/2005

Therapy/Procedure

5Therapeutics
04/2016 - 02/2003
1Aftercare (After-Treatment)
10/2022
1Ambulatory Surgical Procedures (Outpatient Surgery)
04/2016
1Intradermal Injections
04/2012
1Phototherapy (Light Therapy)
09/2011
1Radiotherapy
11/2010
1Biological Therapy
06/2007
1Immunotherapy
02/2005